pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
Oct 14, 26
Immune Boost Capital Invests in Orthrus Therapeutics to Advance Antigen-Specific Immune Tolerance for Autoimmune Disease
fiercebiotech
Oct 14, 26
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
Oct 14, 26
From Scientific Hypothesis to Clinical Practice: The Next Chapter for CLDN18.2
fiercebiotech
Oct 14, 26
Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline
fiercebiotech
Oct 13, 26
Decreasing process variability in fluid management systems
biopharma dive
Oct 13, 26
Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs
fiercebiotech
Oct 13, 26
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
biospace
Oct 13, 26
Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
biospace
Oct 13, 26
Biotech builder Paragon imports Apogee's top brass after AbbVie buyout
fiercebiotech
Oct 12, 26
How to boost throughput and data quality for stability testing of biologics
biospace
Oct 11, 26
The 2026 Biotech Graveyard
fiercebiotech
Oct 10, 26
Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOs
fiercebiotech
Oct 9, 26
GSK drinks in Chai Discovery’s AI models after wet-lab validation
fiercebiotech
Oct 9, 26
How we picked the Fierce 15
fiercebiotech
Oct 9, 26
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
Oct 8, 26
Chutes & Ladders—Vir looks to Liu to lead late-stage push
fiercebiotech
Oct 8, 26
Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for Vyvgart
biospace
Oct 8, 26
STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
stat
Oct 8, 26
On the move: 4 rare disease companies hiring now
biospace
Oct 8, 26
Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
fiercebiotech
Oct 7, 26
Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDA
biospace
Oct 7, 26
ArriVent sheds nearly half of value on late-stage lung cancer miss
biospace
Oct 7, 26
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
biospace
Oct 7, 26
5 biggest venture capital raises of Q3 2026
biospace
Oct 6, 26
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
biopharma dive
Oct 6, 26
FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues
biospace
Oct 6, 26
AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3
biospace
Oct 6, 26
The top biopharma conferences in 2027
biopharma dive
Oct 6, 26
AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy
endpoints
Oct 6, 26
ArriVent’s phase 3 lung cancer trial flops, sinking stock
fiercebiotech
← prev
page 8 of 27
next →